Amgen Inc
USUSDAmgen Inc (MX:AMGN) — Biotechnology: Biological Products (No Diagnostic Substances). Número de bolsas en las que cotizan las acciones de la empresa: 4. En esta página: cotización y gráfico, dividendos, principales accionistas e historial del número de acciones.
Sobre la Empresa
- Sitio Web
- amgen.com
- Relaciones con los Inversores
- investors.amgen.com/
- Sector
- Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
- Sede Central
- Thousand Oaks, United States
- Consejero Delegado
- Robert A. Bradway
- Empleados
- 17 900
- Fundada
- 1980
- Cotiza Desde
- 29.02.2008 (MX:AMGN)
- Acciones en Circulación
- 540.63 M a 2026-07-30
- Capital Flotante
- 539.16 M
- Capitalización Bursátil
- 226.05 mil M USD
- Insiders
- 0.23%
- Inversores Institucionales
- 85.02%
- Industria (SIC)
- Biological Products, (No Diagnostic Substances)
- Forma Jurídica
- XTIQ
- ISIN
- US0311621009
- LEI
- 62QBXGPJ34PQ72Z12S66
- P/E
- 25.9
- Ratio de Reparto
- 60.4%
- FCF
- 10.2 mil M USD
- Pagos / FCF
- 52%
- Deuda
- 57.3 mil M USD4.3 a. de FCF
- Racha de Dividendos
- 15 a.
- Beneficios, FCF y dividendos pagados — para los 12 meses hasta 30.06.2026 (el último informe de la compañía).
Descripción
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Bolsas y Tickers
| Bolsa | Ticker | Moneda | Precio | Tipo |
|---|---|---|---|---|
| US USA Stocks | AMGN principal | USD | 417.57 +0.65% | acciones ordinarias |
| HK Hong Kong Stock Exchange | 4332 secundaria | HKD | — | |
| LSE London Stock Exchange | 0R0T IOB | USD | 411.854 +1.17% | acciones ordinarias |
| MX Mexican Stock Exchange | AMGN secundaria | MXN | 7 500.0098 +0.00% | acciones ordinarias |
| XETRA Xetra | AMG secundaria | EUR | 367.95 -1.39% | acciones ordinarias |
Dividendos
Amgen Inc (AMGN) paga dividendos trimestralmente. Por año (12 meses hasta e incluyendo el último pago anunciado): 180.7291 MXN por acción (pagos: 4). Eso representa aproximadamente el 2.41% del precio actual de la acción. Según el historial de pagos, se espera la próxima fecha ex-dividendo alrededor de 20.11.2026. Historial de dividendos ininterrumpido: 15 años.
| Fecha Ex | Pago | Importe | % | Tipo | Ticker |
|---|---|---|---|---|---|
| 2026-08-21 | — | 45.8186 MXN | 0.6/2.4 % | trimestral | MX:AMGN |
| 2026-05-15 | — | 45.8186 MXN | 0.8/3.1 % | trimestral | MX:AMGN |
| 2026-02-13 | — | 45.8186 MXN | 0.7/2.8 % | trimestral | MX:AMGN |
| 2025-11-21 | — | 43.2732 MXN | 0.7/2.8 % | trimestral | MX:AMGN |
| 2025-08-22 | — | 43.2732 MXN | 0.8/3.1 % | trimestral | MX:AMGN |
| 2025-05-16 | — | 43.2732 MXN | 0.8/3.1 % | trimestral | MX:AMGN |
| 2025-02-14 | — | 43.2732 MXN | 0.7/2.7 % | trimestral | MX:AMGN |
| 2024-11-19 | — | 40.9095 MXN | 0.6/2.5 % | trimestral | MX:AMGN |
| 2024-08-16 | — | 40.9095 MXN | 0.7/2.7 % | trimestral | MX:AMGN |
| 2024-05-16 | — | 40.9095 MXN | 0.8/3.2 % | trimestral | MX:AMGN |
| 2024-02-15 | — | 40.9095 MXN | 0.8/2.9 % | trimestral | MX:AMGN |
| 2023-11-16 | — | 38.7277 MXN | 0.8/3.3 % | trimestral | MX:AMGN |
| 2023-08-17 | — | 38.7277 MXN | 0.8/3.3 % | trimestral | MX:AMGN |
| 2023-05-17 | — | 38.7277 MXN | 0.9/3.6 % | trimestral | MX:AMGN |
| 2023-02-14 | — | 38.7277 MXN | 0.8/3.1 % | trimestral | MX:AMGN |
| 2022-11-16 | — | 35.2731 MXN | 0.7/2.6 % | trimestral | MX:AMGN |
| 2022-08-17 | — | 35.2731 MXN | 0.7/2.8 % | trimestral | MX:AMGN |
| 2022-05-16 | — | 35.2731 MXN | 0.7/2.1 % | trimestral | MX:AMGN |
| 2022-02-14 | — | 35.2731 MXN | 0.7/1.4 % | trimestral | MX:AMGN |
| 2021-11-16 | — | 32.0003 MXN | 0.7/0.7 % | trimestral | MX:AMGN |
Principales Accionistas
| Titular | Participación | Acciones | Fecha del Informe |
|---|---|---|---|
| Blackrock Inc. | 9.13% | 49.36 M | 2026-06-30 |
| Vanguard Capital Managem… | 6.52% | 35.25 M | 2026-06-30 |
| State Street Corporation | 5.65% | 30.56 M | 2026-06-30 |
| Capital World Investors | 5.38% | 29.08 M | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 3.17% | 17.13 M | 2026-06-30 |
| Invesco Ltd. | 3.02% | 16.32 M | 2026-06-30 |
| Geode Capital Management… | 2.9% | 15.7 M | 2026-06-30 |
| Charles Schwab Investmen… | 2.78% | 15.03 M | 2026-06-30 |
| Vanguard Portfolio Manag… | 2.75% | 14.85 M | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.59% | 13.99 M | 2026-06-30 |
| Morgan Stanley | 2.53% | 13.65 M | 2026-06-30 |
| Invesco QQQ Trust, Serie… | 2.15% | 11.61 M | 2026-08-31 |
| SCHWAB STRATEGIC TRUST-S… | 1.81% | 9.79 M | 2026-05-31 |
| Income Fund of America | 1.44% | 7.76 M | 2026-06-30 |
| iShares Trust-iShares Co… | 1.35% | 7.28 M | 2026-07-31 |
| Wells Fargo & Company | 1.34% | 7.24 M | 2026-06-30 |
| AMERICAN BALANCED FUND | 1.31% | 7.09 M | 2026-06-30 |
| Fidelity Concord Street… | 1.29% | 6.98 M | 2026-07-31 |
| SPDR S&P 500 ETF TRUST-S… | 1.22% | 6.6 M | 2026-08-31 |
| WASHINGTON MUTUAL INVEST… | 1.16% | 6.27 M | 2026-06-30 |
| BRADWAY ROBERT A (Chief… | ≈0.12% | 657 299 | 2026-05-05 |
| SANTOS ESTEBAN (Officer) | ≈0.02% | 84 279 | 2026-05-05 |
| GORDON MURDO (Officer) | ≈0.01% | 51 837 | 2026-05-05 |
| GRIFFITH PETER H. (Chief… | ≈0.01% | 50 706 | 2026-05-05 |
| REESE DAVID M. (Chief Te… | ≈0.01% | 42 812 | 2026-05-05 |
| GRAHAM JONATHAN P (Gener… | ≈0.01% | 40 211 | 2026-05-05 |
| BRADNER JAMES E. (Office… | ≈0.01% | 30 462 | 2026-05-05 |
| ECKERT ROBERT ANDREW (Di… | ≈0% | 26 251 | 2026-05-19 |
| JACKS TYLER (Director) | ≈0% | 18 284 | 2026-05-19 |
| KULLMAN ELLEN JAMISON (D… | ≈0% | 14 536 | 2026-05-19 |
